The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and ...

Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown ... The SUMMIT trial enrolled obese patients with heart failure with preserved ejection fraction (HFpEF) – a particularly hard ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

An international team of researchers at the University of Manchester, Baylor College of Medicine and collaborating institutions has discovered a natural mechanism that protects the heart from heart ...

people with heart failure with preserved ejection fraction (HFpEF) who were able to travel outside of their home without assistance ... Preclinical Study: After Heart Attack, a Boost in Anti ...

and Heart Failure (preserved [HFpEF] and reduced [HFrEF] ejection fraction). We reported hazard ratios [HR] from Cox Proportional Hazards models adjusting for age, sex, and medications (statin, ...

Use of routine thoracentesis in addition to medical therapy yielded no significant benefits for adults with heart failure and ...